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Liver regeneration is controlled by a panoply of 
factors performing diverse functions, includ-
ing cytokine signaling (suppressor of cytokine 
signaling 3 [Socs3], IL-6, and Tnf; Feingold 
et al., 1988; Sakamoto et al., 1999; Zimmers et al., 
2003; Riehle et al., 2008), transcription (NF-b 
and Stat3; Cressman et al., 1994, 1995), growth 
factor response (egf [epidermal growth factor] and 
TGF-; Russell, 1988; Jones et al., 1995), glu-
cose metabolism (Bucher and Swaffield, 1975), 
bile acid metabolism (Huang et al., 2006), and 
platelet-derived signaling involving both extracel-
lular nucleotides (Beldi et al., 2008) and serotonin 
(Lesurtel et al., 2006). Advances in defining and 
characterizing these signals leave unanswered the 
fundamental question of how multiple inputs are 
integrated into the discrete functional response of 
hepatocyte proliferation after injury.
Restoration of liver mass requires stimula-
tory inputs. Inhibition or removal of IL-6, Stat3, 
Egf, c-Jun, or serotonin, among others, delays 
liver regeneration (Jones et al., 1995; Sakamoto 
et al., 1999; Selzner and Clavien, 2000; Lesurtel 
et al., 2006; Natarajan et al., 2007; Moh et al., 
2007). Furthermore, addition of a variety of 
molecules, including IL-6, HGF (hepatocyte 
growth factor), and thyroid hormone, enhances 
liver regeneration (Francavilla et al., 1994; Ogura 
et al., 2001; Zimmers et al., 2003).
Direct evidence that reduction in inhibitory 
inputs is critical for restoration of liver mass after 
injury has been more difficult to obtain, and this 
remains a highly likely but poorly understood 
paradigm. Clearly, inhibitory inputs must play 
some role. For example, both TGF- and its 
family member activin inhibit liver regenera-
tion, and the activin antagonist follistatin en-
hances regeneration (Jakowlew et al., 1991; 
Schwall et al., 1993; Kogure et al., 1995). These 
experiments, however, which were performed 
with pharmacologic doses of the molecules, do 
not identify the actual mediator. Furthermore, 
both TGF-1 and activin A are increased after 
partial hepatectomy, making it difficult to con-
clude that either molecule inhibits regeneration 
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How proliferative and inhibitory signals integrate to control liver regeneration remains 
poorly understood. A screen for antiproliferative factors repressed after liver injury identi-
fied transducer of ErbB2.1 (Tob1), a member of the PC3/BTG1 family of mito-inhibitory 
molecules as a target for further evaluation. Tob1 protein decreases after 2/3 hepatectomy 
in mice secondary to posttranscriptional mechanisms. Deletion of Tob1 increases hepatocyte 
proliferation and accelerates restoration of liver mass after hepatectomy. Down-regulation 
of Tob1 is required for normal liver regeneration, and Tob1 controls hepatocyte prolifera-
tion in a dose-dependent fashion. Tob1 associates directly with both Caf1 and cyclin-
dependent kinase (Cdk) 1 and modulates Cdk1 kinase activity. In addition, Tob1 has 
significant effects on the transcription of critical cell cycle components, including E2F 
target genes and genes involved in p53 signaling. We provide direct evidence that levels of 
an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial 
check point molecule that modulates the expression and activity of cell cycle proteins.
© 2010 Ho et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Tob1 mRNA and protein levels decline  
after partial hepatectomy
To determine how Tob1 mRNA levels change as liver mass is 
restored, real-time PCR was performed on regenerating liver 
after 2/3 hepatectomy in C57B/6 mice (Fig. 1 A). There is high 
baseline Tob1 mRNA expression in the uninjured liver (time 
0). Levels decline acutely but recover by 24 h, reaching base-
line by 48 h after hepatectomy. At 6 and 12 h after hepatec-
tomy, these differences were significant (n = 3–9 animals). 
In contrast, no changes in Tob1 mRNA expression were ob-
served in sham-operated control mice (unpublished data).
Nuclear localization and phosphorylation state of Tob1 
were analyzed separately by Western blotting (Fig. 1 B). In 
response to 2/3 hepatectomy, cytoplasmic protein levels of both 
Tob1 and p-Tob1 decrease by 24 h, are nearly undetectable 
by 36 h, and begin to recover by 72 h, reaching basal levels 
by 144 h. Nuclear levels of Tob1 and p-Tob1 are generally 
lower overall. Levels decline by 24 h after hepatectomy and, 
by 36 h, are nearly undetectable. Recovery begins by 144 h after 
injury. Purity of cytoplasmic and nuclear fractions was verified 
by blotting for -actin (cytoplasmic) and histone H3 (nuclear), 
which also served as loading controls. No changes in Tob1 
protein expression occurred in sham-operated mice (unpub-
lished data). Collectively, our results suggest that Tob1 protein 
decreases after hepatectomy, primarily via posttranscriptional 
mechanisms. Because the proportion of Tob1 that is phos-
phorylated does not change dramatically over time, decreases 
in levels of p-Tob1 are likely a result of protein degradation 
and not dephosphorylation.
Liver regeneration after partial hepatectomy is accelerated 
in Tob1-null mice.
To determine the functional consequences of loss of Tob1, 
comparisons were made between WT and Tob1-null mice. 
Western blot analysis confirmed disruption of the Tob1 gene 
indicated by undetectable levels of Tob1 protein, which is 
consistent with published results (Yoshida et al., 
2000, 2003a; and not depicted). Adult Tob1-null 
mice and their WT littermates demonstrate similar 
baseline liver/body weight ratio, exhibit similar min-
imal baseline hepatocyte proliferation as measured 
after hepatectomy (Ueda et al., 2003; Takamura et al., 2005; 
Michalopoulos, 2007). Similarly, although mice with deletions 
in Socs3 or p21 exhibit enhanced liver regeneration, both are 
induced after hepatectomy, suggesting they are not direct in-
hibitors of hepatocyte proliferation (Stepniak et al., 2006; Riehle 
et al., 2008). Other candidate inhibitors of hepatocyte prolif-
eration, including p27 and CCAAT enhancer binding protein  
(C/ebp-), are difficult to study because of baseline size or met-
abolic abnormalities in null mice (Flodby et al., 1996; Hayashi 
et al., 2003).
Constitutive repressors that control the rate of hepatocyte 
proliferation may be defined by the following characteristics: 
baseline concentrations that are decreased after hepatectomy, 
enhancement of hepatocyte proliferation in mice with tar-
geted deletion, and prevention of normal regeneration when 
maintained at high levels. To find such molecules, we under-
took a screen for genes that decrease after partial hepatectomy 
and might have antimitotic activity.
We then focused on transducer of ErbB2.1 (Tob1) based 
on our characterization of its expression pattern after hepa-
tectomy and its known antiproliferative functions (Otu et al., 
2007). Initially identified by interactions with p185erbB2, 
proteins in the Tob1 family regulate cell cycle (Matsuda et al., 
1996; Yoshida et al., 2000, 2003a). Nuclear localization and 
phosphorylation are critical for Tob1 function, which occurs 
via at least two distinct mechanisms (Suzuki et al., 2002; 
Kawamura-Tsuzuku et al., 2004). The first is to influence 
cyclin-dependent kinase (Cdk) activity by binding to Caf1, and 
the second is to modulate mRNA degradation by regulating 
the first step of the process, deadenylation (Ikematsu et al., 1999; 
Tucker et al., 2001; Temme et al., 2004; Ezzeddine et al., 
2007; Nishida et al., 2007). In this paper, we show that Tob1 
fulfills the criteria for a critical constitutive inhibitor of hepa-
tocyte proliferation, and we provide evidence that Tob1 acts 
as an integrative molecule to control the rate of hepatocyte 
proliferation after hepatectomy by influencing the activity 
and expression of cell cycle proteins.
Figure 1.  Tob1 mRNA expression and protein levels 
are decreased after 2/3 hepatectomy. (A) Real-time PCR 
of Tob1 mRNA in liver samples at various intervals after hep-
atectomy. *, P = 0.05; **, P = 0.001. Each time point consists 
of at least three and as many as nine animals. Error bars in 
this and all other figures are standard error. (B) Western blot 
analysis of total and phosphorylated Tob1 protein in whole 
cell and nuclear extracts at various times after 2/3 hepatec-
tomy. -Actin demonstrated the purity of the cytoplasmic 
fraction, whereas histone H3 demonstrated the purity of the 
nuclear fraction. Both serve as loading controls. All blot lanes 
are the most representative sample from among at least 
three different animals.JEM VOL. 207, June 7, 2010 
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Tob1  expression  in  mice  receiving 
MUP-Tob1-AAV8  was  robust  and 
above the level of mice receiving no 
virus or MUP-eGFP-AAV8. As ex-
pected from the use of the MUP pro-
moter to drive Tob1 expression, Tob1 
protein  expression  was  maintained 
through  48  h  after  hepatectomy 
(Fig.  3  A, *). Tob1 expression was 
maintained through 3 wk after injection 
(unpublished data). Each band shown 
is the most representative band from 
among three separate animals. These 
data show that MUP-Tob1-AAV8 ef-
ficiently expresses recombinant protein 
2 wk after injection. They also demon-
strate that expression from the MUP promoter is high enough 
to overcome any degradation mechanisms after hepatectomy.
Tob1 levels control the rate of hepatocyte proliferation 
after partial hepatectomy
To precisely manipulate Tob1 levels, we performed reconsti-
tution experiments in which Tob1-null mice were infected 
with MUP-Tob1-AAV8 so that the only source of Tob1 
would be the virus. To determine optimal dosing of the virus, 
we noted that immunofluorescence for eGFP demonstrated 
that 5 × 1010 DNase-resistant particles (DRPs) of MUP-eGFP-
AAV8 produces protein expression in 90% of hepatocytes, 
whereas at 2.5 × 1010 DRP, 50% of hepatocytes express (un-
published data). These doses were used for MUP-Tob1-AAV8. 
As the amount of virus was increased, proliferation rates de-
creased 48 h after hepatectomy (Fig. 3 B). Mice receiving 5 × 1010 
DRP of MUP-Tob1-AAV8 demonstrated lowest prolifera-
tion of hepatocytes after hepatectomy, whereas mice with   
2.5 × 1010 DRP MUP-Tob1-AAV8 or 5 × 1010 DRP control 
MUP-eGFP-AAV8 virus exhibited progressively higher levels 
of hepatocyte proliferation (P < 0.05 between all groups). To 
verify that Tob1 protein levels decrease in the predicted fash-
ion, Western blotting was performed on liver lysates prepared 
from specimens at 48 h (Fig. 3 C). 5 × 1010 DRP of virus pro-
duced the highest amount of Tob1 protein, whereas 2.5 × 1010 
DRP produced a lower level. These results demonstrate that 
Tob1 levels control the rate of hepatocyte proliferation after 
hepatectomy in a dose-dependent fashion.
by BrdU labeling, and have similar histology (Fig. 2 A and 
not  depicted).  After  partial  hepatectomy,  Tob1-null  mice 
demonstrate a faster recovery of liver/body weight ratio 
beginning at 72 h and continuing through 96 h (Fig. 2 A; 
n = 3–6). Liver/body weight ratios are equivalent 9 d after 
partial hepatectomy when the ratio returns to normal. Tob1-null 
mice demonstrate more rapid onset of hepatocyte prolifera-
tion and higher absolute percentage of proliferating hepato-
cytes from 36 to 96 h after hepatectomy compared with WT 
littermates (Fig. 2, B and C; n = 3–6). These results demon-
strate that Tob1 functions to decrease the pace of regenera-
tion after hepatectomy.
Mouse urinary protein (MUP)–Tob1–adeno-associated  
virus 8 (AAV8) expresses Tob1 protein in the liver
We next investigated whether hepatocyte proliferation rates 
depend on Tob1 protein levels. To answer this question, 
it was necessary to develop a system in which Tob1 protein 
levels could be precisely manipulated. To accomplish this, we 
assembled an AAV8 with an MUP promoter to drive Tob1 
expression in the liver (MUP-Tob1-AAV8; Ho et al., 2008).
To determine the time course of expression of Tob1 in 
mice injected with MUP-Tob1-AAV8, Western blotting was 
performed at different times after injection (Fig. 3 A). 1 wk 
after injection, there was no difference between Tob1 pro-
tein levels in control mice who received no virus (NaCl), a 
control virus containing enhanced GFP (eGFP; MUP-eGFP-
AAV8), or the MUP-Tob1-AAV8. By 2 wk after injection, 
Figure 2.  Loss of Tob1 enhances liver 
regeneration and hepatocyte proliferation 
after hepatectomy. (A) 2/3 hepatectomy was 
performed on Tob1-null and WT mice. Resto-
ration of liver mass was measured by liver/
body weight (bw) ratio at the indicated time 
points. n = 3–6 per time point. *, P = 0.03; 
**, P = 0.001. (B and C) BrdU incorporation in 
the liver at indicated time points after 2/3 
hepatectomy. n = 3–6. *, P < 0.001; **, P = 0.008; 
***, P = 0.01; ****, P = 0.007. Bar, 150 µM.1200 Tob1 regulates liver regeneration | Ho et al.
cluded both a rabbit and a mouse IgG. Positive control lanes 
consisted of whole cell lysates (unpublished data). These re-
sults demonstrate that all three proteins colocalize in a com-
mon complex. Our data provide mechanistic support for the 
hypothesis that Tob1 modulates Cdk activity by direct asso-
ciation with the cyclin–cdk complex.
Effect of loss of Tob1 on pathways critical  
for liver regeneration
To place Tob1 in the context of the many factors known to 
be involved in liver regeneration, we performed several studies 
of the effect of Tob1 deletion on other genes. We first studied 
how loss of Tob1 affected the cell cycle proteins cyclin D1 
and A2. Cyclin D1 is important for initiation of DNA syn-
thesis, whereas cyclin A2 drives the transition to mitosis from 
S phase (Malumbres and Barbacid, 2009). At baseline, mRNA 
for cyclin D1 is increased in Tob1-null compared with WT 
mice (n = 3; Fig. 5 A). Although there are no significant 
changes in cyclin A2 mRNA expression in the Tob1-null 
mice compared with WT mice, protein levels of both cyclins 
increase faster in the Tob1-null mice (Fig. 5 B). In particular, 
cyclin D1 is increased more strongly by 24 h continuing 
through 36 h, whereas cyclin A is more robustly expressed by 
24 h. These results show that Tob1 inhibits cyclin D1 expres-
sion at baseline and acts to delay the rise in both cyclin D1 
and A2 necessary for cell division. Therefore, after hepatec-
tomy, decreases in Tob1 would be expected to allow in-
creases in cyclin D1 and A2 that are necessary for normal 
hepatocyte proliferation.
Effect of Loss of Tob1 on kinase activity
Tob1 associates with a variety of proteins and has multiple 
functions including a critical role in early G1 progression 
(Matsuda et al., 1996; Yoshida et al., 2000, 2003a). In particular, 
Tob1 modulates Cdks via interaction with Caf1 to influence 
cell cycle progression (Ikematsu et al., 1999; Nishida et al., 2007). 
To determine whether modulation of Cdk1 activity might ex-
plain the effect of Tob1 on liver regeneration, we performed 
kinase assays in WT mice, Tob1-null mice, and Tob1-null mice 
with MUP-Tob1-AAV8 or control MUP-eGFP-AAV8 virus. 
Consistent with this hypothesis, compared with WT mice, he-
patic Cdk1 kinase activity was increased in Tob1-null mice. This 
activity was reduced to normal levels with the introduction of 
MUP-Tob1-AAV8 to the Tob1-null mice (Fig. 4 A, Tob1 null: 
174 ± 17.9; Tob1 null with MUP-Tob1-AAV8: 117.4 ± 13.4; 
Tob1 null with MUP-eGFP-AAV8: 180.2 ± 13.1; WT C57B/6: 
118.75 ± 9.75; n = 4–6, P = 0.035 and P = 0.036). These 
results suggest that Tob1 modulates cell cycle progression by 
inhibiting Cdk1 kinase activity.
Tob1 and Caf1 associate with the cyclin–cdk complex
To further elucidate the mechanism of action of Tob1, we 
tested whether Tob1 and Caf1 associate with the cyclin–cdk 
complex in the liver. To accomplish this, multiple coimmuno-
precipitation experiments were performed. Using antibodies 
to Cdk1, both Tob1 and Caf1 were precipitated. Similarly, 
antibodies to Tob1 coimmunoprecipitated both Cdk1 and Caf1. 
Finally, antibodies to Caf1 coimmunoprecipitated Cdk1 and 
Tob1 in normal adult liver (Fig. 4 B). Negative controls in-
Figure 3.  MUP-Tob1-AAV8 virus inhibits hepa-
tocyte proliferation after hepatectomy in a dose-
dependent fashion. (A) Western blot of mouse liver 
after injection of MUP-Tob1-AAV8, MUP-eGFP-AAV8, 
or NaCl. The asterisk denotes Tob1 expression main-
tained even 48 h after hepatectomy and 2 wk after 
injections. (B) Tob1-null mice were infected with 
indicated doses of MUP-Tob1-AAV8 virus or MUP-
eGFP-AAV8 (control). 3 wk later, 2/3 hepatectomy 
was performed and livers analyzed 48 h after hepa-
tectomy. BrdU labeling is shown. n = 3. *, P = 0.01;  
**, P < 0.05. (C) Western blot of Tob1 in whole cell 
lysates. -Actin is used to demonstrate equal protein 
loading. All blot lanes are the most representative 
sample from among at least three different animals.
Figure 4.  Loss of Tob1 results in in-
creases in Cdk1 activity, and Tob1 and 
Caf1 bind to Cdk1. (A) Cdk1 kinase activity 
in the liver of Tob1-null mice infected or not 
with MUP-Tob1-AAV8 or MUP-eGFP-AAV8.  
n = 4–6. *, P = 0.035; **, P = 0.036. (B) Coim-
munoprecipitation of Cdk1, Tob1, and Caf1.  
IP, immunoprecipitation antibodies; IB, immuno-
blot antibodies. Mouse IgG control is the neg-
ative control. The samples were run on the 
same gel and each lane is the most represen-
tative among three samples.JEM VOL. 207, June 7, 2010 
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normal adult mice and at 6, 24, and 48 h after hepatectomy (un-
published data). Despite baseline p21 levels being higher in 
Tob1-null mice, nuclear and cytoplasmic p21 levels increase in a 
similar fashion in WT and Tob1-null mice (Fig. 6). The presence 
of Tob1, therefore, serves to suppress p21 levels at baseline.
p27 is a negative regulator of cell cycle, and p27-null mice 
accelerate DNA replication after partial hepatectomy (Hayashi 
et al., 2003). To determine whether Tob1 influences p27, 
mRNA and protein levels were examined. Loss of Tob1 has 
no effect on p27 mRNA levels after hepatectomy. p27 protein 
levels are slightly higher at baseline in Tob1-null mice than in 
the WT (Fig. S2). These results suggest that Tob1 functions to 
suppress p27 levels at baseline.
C/ebp- functions as an inhibitor of hepatocyte prolif-
eration and newborn mice lacking C/ebp- exhibit increased 
hepatocyte proliferation (Flodby et al., 1996). There were no 
differences in mRNA levels between Tob1-null mice and WT 
mice. In contrast, Tob1-null mice demonstrated accelerated loss 
of C/ebp- protein after hepatectomy compared with WT 
mice (Fig. 7). These results suggest that Tob1 tends to maintain 
C/ebp- protein levels via posttranscriptional mechanisms.
Tob proteins bind to Smad1, 5, and 8, preventing their 
activity as a transcription factors, and may have a role in their 
translocation to nuclear bodies (Yoshida et al., 2003b; Ross 
and Hill, 2008). To determine whether loss of Tob1 affects 
mRNA or protein levels for these Smads, real-time PCR and 
Western blotting were performed. Loss of Tob1 has no effect 
on mRNA for Smad1 (see Fig. 9 A). In contrast, loss of Tob1 
blocks the robust induction of Smad5, which occurs in WT 
mice after 2/3 hepatectomy (n = 3; Fig. 8 A), and loss of 
Tob1 leads to generally higher levels of Smad8 mRNA after 
We next investigated the effect of loss of Tob1 on cyto-
kine signals Socs3 and IL-6. Both are up-regulated soon after 
partial hepatectomy and are critical for liver regeneration 
(Zimmers et al., 2003; Riehle et al., 2008). No change was 
observed in the mRNA expression of either of these mole-
cules in WT mice versus Tob1-null mice over the initial 48 h 
after hepatectomy (Fig. S1). Both exhibit an acute rise by 6 h 
after injury. These results suggest that Tob1 does not act by 
affecting cytokine transcription.
IL-6 is essential for Stat3 activation via phosphorylation and 
nuclear translocation (Cressman et al., 1994; Zimmers et al., 
2003). To determine if Tob1 influences this pathway, we ex-
amined Stat3 protein levels, phosphorylation, and nuclear lo-
calization in Tob1-null and WT mice. Stat3 protein levels are 
fairly constant and not dramatically different between Tob1-
null and WT littermates, with the exception that nuclear 
Stat3 is higher in WT mice than in Tob1-null mice at base-
line, and nuclear Stat3 increases more robustly in Tob1-null 
mice than in the WT after hepatectomy (Fig. 6). In contrast, 
p-Stat3 is present in both cytoplasmic and nuclear fractions of 
quiescent adult liver from Tob1-null mice but not in WT lit-
termates (Fig. 6, ^ vs. *). In both Tob1 and WT mice, Stat3 
undergoes dramatic activation with markedly increased phos-
phorylation by 6 h after hepatectomy. These results suggest that 
at baseline, Tob1 helps to suppress hepatocyte proliferation by 
suppressing Stat3 phosphorylation and therefore its activation.
Repression of p21 activity is required for hepatocyte pro-
liferation after hepatectomy (Stepniak et al., 2006). To deter-
mine the effect of loss of Tob1 on p21, we examined mRNA 
and protein expression in Tob1-null mice compared with WT 
littermates. p21 mRNA is induced in both Tob1-null and WT 
Figure 5.  Cyclin D1 and A2 expression increase more quickly in Tob1-null mice compared with WT controls. (A) Real-time PCR of cyclin D1 
and cyclin A2 mRNA at indicated time points after hepatectomy. Each point represents at least three mice. *, P = 0.012. (B) Cyclin D1 and A2 protein was 
measured by immunoblot at indicated time points after hepatectomy. -Actin was the loading control. All lanes are the most representative of three sep-
arate animals. Each row was run on the same gel, and the break represents portions of the gel not shown.
Figure 6.  Loss of Tob1 affects expression of proteins 
important for restoration of liver mass after injury. 
Total and phosphorylated Stat3 and p21 in the liver of 
Tob1-null mice and WT littermates was measured by  
immunoblot at indicated time points after hepatectomy. 
-Actin and histone H3 were loading controls for the 
cytoplasmic and nuclear extracts, respectively. Note the 
presence of p-Stat3 in quiescent adult liver from Tob1-
null mice but not in WT littermates (^ vs. *). All samples 
were run on the same gel and each lane is the most repre-
sentative among three samples.1202 Tob1 regulates liver regeneration | Ho et al.
mass. Tob1 levels decrease after hepatectomy in WT mice, so 
that Tob1-null mice can be considered to have an accelerated 
loss of Tob1. Because Tob1 has no effect on baseline hepato-
cyte proliferation and there is a clear effect by 36 h, we chose 
24 h to analyze, a time between these points which we rea-
soned would give enough time for transcriptional differences 
to become apparent.
To perform this analysis, we constructed a list of genes 
significantly changed in the WT compared with normal adult 
liver after hepatectomy and a separate list of genes significantly 
changed in the Tob1-null mice 24 h after partial hepatectomy 
compared with uninjured livers from Tob1-null mice. We ar-
ranged these in a Venn diagram and chose only genes signifi-
cantly changed in the Tob1-null and not in the WT mice for 
further analysis.
We  chose  a  threshold  for  differential  regulation  as  a 
lower confidence bound (LCB) > |1.2| (see Irizarry et al., 
2003 and Otu et al., 2007 for algorithms and methods). 
This was chosen because the LCB is a stringent estimate of 
differential expression and most likely corresponds to an ac-
tual difference of >1.2. This level was chosen prospectively 
as the most accurate choice for reliable differential expres-
sion. Using this threshold, there were 616 genes induced in 
the Tob1-null mice at 24 h after hepatectomy that were not 
induced in the WT mice at this time point. We note 969 
genes are induced in the WT mice that were not induced in 
the Tob1-null mice after hepatectomy.
To validate this entire dataset, a total of 20 genes were 
interrogated using real-time PCR. Examining each gene in 
hepatectomy (n = 3). Nuclear Smad protein levels are generally 
lower in Tob1-null mice. Because Smad signaling occurs via 
phosphorylation and nuclear localization, a better measure of 
the action of Tob1 on Smad signaling is to look at activation. 
In this case, nuclear levels of phosphorylated Smads are re-
markably similar between Tob1-null mice and their litter-
mates. Interestingly, Smad activation decreases dramatically 
by 24 h after hepatectomy in both Tob1-null and WT mice 
(Fig. 8 B). This data suggests that although Tob1 has effects 
on Smad mRNA transcription and protein levels, Tob1 does 
not directly impact Smad activation.
Absence of Tob1 affects expression of genes involved  
in a variety of pathways
To provide further insight into how loss of Tob1 enhances 
liver regeneration after partial hepatectomy, we performed   
microarray analysis of samples from WT and Tob1-null mice 
as normal adults and 24 h after 2/3 hepatectomy. Each ex-
perimental point (e.g., WT at 24 h after hepatectomy) used 
data from two chips, each with a different set of three pooled   
animals. Each chip was run in duplicate. Affymetrix 2.0   
chips containing >45,000 oligonucleotides were used. The full 
dataset is available from GEO under the accession number 
GSE21836.
Analyzing the effect of deletion of a specific gene using 
microarray data can be performed in several ways to answer 
different questions. To maximize the relevance of the conclu-
sions, we reasoned as follows: Tob1 loss is the critical event in 
accelerating hepatocyte proliferation and restoration of liver 
Figure 7.  Effect of loss of Tob1 on C/EBP-. (A) C/EBP- mRNA was measured by real-time PCR in the liver of Tob1-null and WT littermates at indi-
cated time points after hepatectomy. n = 3. P = NS. (B) C/EBP- protein was measured by immunoblot. -Actin was the loading control. All lanes are the 
most representative of three separate animals.
Figure 8.  Loss of Tob1 does not change 
Smad activation. (A) Smad1, Smad5, and 
Smad8 mRNA was measured by real-time PCR 
in the liver of Tob1-null (KO) and WT (WT) 
mice at different times after hepatectomy  
(n = 3; *, P = 0.001) and increased Smad8 
expression at 24 h (n = 3; **, P = 0.01). Each 
point represents at least three mice. (B) Total 
and phosphorylated Smad 1/5/8 protein was 
measured by immunoblot in nuclear extracts 
of Tob1-null mice. -Actin and histone H3 
immunoblots demonstrate purity of the nu-
clear extracts and serve as a loading control. 
All lanes are the most representative of three 
separate animals.JEM VOL. 207, June 7, 2010 
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followed by insulin-like growth factor 1 signaling, with   
P = 0.00004. The full dataset can be found in Table S2.
Loss of Tob1 influences transcriptional pathways
To better understand the transcription factors and pathways af-
fected by the loss of Tob1, we used promoter analysis and inter-
action network toolset (PAINT). This algorithm takes an input 
set of genes, in our case the genes differentially expressed in the 
Tob1-null mice, and identifies transcriptional response elements 
(TREs) in the flanking or known promoter regions of the input 
gene list that are predicted to bind to known transcription fac-
tors. In this way, PAINT helps form a picture of which of a 
smaller number of genes (the transcription factors) are responsible 
for the larger number of changes in gene expression patterns.
Using our dataset, this analysis identified several transcription 
factors  expected  to  bind  to  these  regions,  including  Ets-1, 
FoxD3, Cre-BP1, E2F, and c-Jun (Table S1). This is evidence 
that these transcription factors play a role in many of the gene 
expression patterns observed in the Tob1-null mice. Because 
E2F targets are important for many cellular processes, including 
cell cycle regulation, we then looked at these genes by category 
according to the gene list generated by Bracken et al. (2004; Fig. 
S4). To determine which of these are predominately affected by 
loss of Tob1, our input list included only genes induced in Tob1-
null mice but not WT mice at 24 h. Analysis of this list revealed 
that most were involved in DNA repli-
cation.  These  results  suggest  that  the 
presence of Tob1 inhibits E2F targets 
responsible for S phase.
both WT and Tob1-null mice between 0 and 24 h gener-
ated 40 relationships that could be characterized as increased,   
decreased, or not changed. For the array data, an LCB > |1.2| 
was considered a change, whereas for the real-time PCR 
data, a p-value of <0.05 was considered a change. In 34 of 
these 40 (85%), the real-time data and the array data were 
concordant (Fig. S3).
We next identified networks differentially regulated in the 
Tob1-null mice compared with WT mice. This type of analysis 
is complementary to individual gene information and may be 
more robust because it examines many genes to identify biologi-
cal processes. To accomplish this, a score was generated (Inge-
nuity Systems software) that takes into account the number of 
genes in the network and the size of the network. It allows a cal-
culation of the approximate fit between each network and the 
genes from the input dataset, allowing the network to be ranked. 
The score is a p-value calculation to determine the possibility 
that the network shown could be found by random chance. 
Analysis of this set of genes, in which expression changed be-
tween 0 and 24 h after hepatectomy in the Tob1-null mice but 
not in WT mice, allowed identification of pathways affected by 
loss of Tob1. We limited our analysis to pathways with P < 0.01, 
given the large number of pathways and genes examined. 20 
pathways were identified in this manner. The most significant 
pathway affected was p53 signaling (Fig. 9), with P < 106, 
Figure 9.  Gene interaction networks 
affected by loss of Tob1. A dataset of genes 
regulated in the Tob1-null mice (LCB > |1.2|), 
but not in WT mice, was used to determine 
how loss of Tob1 affects gene expression after 
2/3 hepatectomy. From this gene list input, a 
score was determined that ranks networks 
according to how relevant they are to the 
genes in the input dataset (see Results). The 
score for the p53 network was 34, the nega-
tive exponent of the p-value (P = 1034), and 
this network is shown here. Each gene is 
given a heat map color that corresponds to 
the degree of regulation; reds are increased 
and greens are decreased, both in proportion 
to the intensity of the color. Numbers repre-
sent fold change. Shapes denote function as 
follows: trapezoids, transporters; diamonds, 
enzymes; ovals, transcription regulators; tri-
angles, kinases; rectangles, ion channels; dou-
ble circles, complex; circles, other. Arrows 
denote the first molecule acts on the second, 
and perpendicular lines denote the first inhib-
its the second. Solid lines are direct interac-
tions, and dashed lines are indirect 
interactions. Data are from two distinct chips, 
each with three different animals.1204 Tob1 regulates liver regeneration | Ho et al.
presses increases in PCNA, cyclins, and cdk2-associated ki-
nase activity, p27, which inhibits cell cycle progression, and 
C/ebp-,  which  interacts  with  the  cyclin–Cdk  complex 
(Albrecht et al., 1998; Greenbaum et al., 1998; Wang et al., 
2001; Kossatz et al., 2004; Weymann et al., 2009). Increased 
levels of p21 and p27 observed in Tob1-null mice suggest that 
these antiproliferative proteins may be responding to or com-
pensating for a primed hepatocyte to prevent proliferation. 
Contrast this with the more rapid decrease in C/ebp- in 
Tob1-null mice, suggesting that Tob1 helps maintain C/ebp-. 
It is tempting to suggest, therefore, that Tob1 and C/ebp- 
are regulated along the same molecular signaling pathway, 
whereas p21 and p27 may be part of a separate pathway.
Dysregulation of p53 signaling identified by array analysis 
suggests an additional mechanism for Tob1 in cell cycle pro-
gression. p53, an important tumor suppressor, can initiate cell 
cycle arrest during times of stress (Boehme and Blattner, 2009). 
In addition, there is an additive effect on tumorigenesis when 
p53 and Tob1 are simultaneously deleted (Yoshida et al., 2003a). 
Collectively, these and our results place Tob1 as a possible me-
diator of p53 activity on the cell cycle.
Temporally, major changes in Tob1 protein levels occur 
after cytokine up-regulation in response to hepatectomy. It is 
therefore not surprising that loss of Tob1 has minimal effects 
on mRNA for either IL-6 or Socs3. Our findings that both 
are increased after hepatectomy are consistent with published 
data (Sakamoto et al., 1999; Campbell et al., 2001). IL-6 pro-
motes Stat3 activation and Socs3 is part of a negative-feedback 
loop to inhibit Stat3 activation. We find, consistent with 
published results, that Stat3 is activated after hepatectomy 
(Cressman et al., 1994; Zimmers et al., 2003; Riehle et al., 
2008). In addition, our finding that Stat3 is activated even in 
quiescent livers in Tob1-null mice suggests that Tob1 may 
influence  cytokine  signaling  not  by  influencing  cytokine 
transcription but rather at the signal transduction level.
Tob1 binds to the downstream effectors of Bmp signal-
ing, including Smad1, 5, and 8, and promotes their localiza-
tion to the nucleus (specifically the nuclear bodies), which 
may result in the suppression of their activity. BMP signals 
are transduced by Smad phosphorylation and nuclear translo-
cation (Feng and Derynck, 2005). Although Smad protein 
levels  and  mRNA  are  altered  in  Tob1-null  mice,  are  no 
changes in the level or phosphorylation of Smads in WT ver-
sus Tob1-null mice, arguing that Tob1 does not have a direct 
effect on Smad signaling.
Tob1 affects the transcription of targets of the transcrip-
tion factors Ets-1, FoxD3, Cre-BP1, E2F, and c-Jun. Ets-1 
binds to a portion of the p53 promoter and may regulate its 
signaling (Baillat et al., 2009). FoxD3 is important for regu-
lating endodermal-specific promoters (Guo et al., 2002). 
Cre-BP1 forms a homodimer or heterodimer with c-Jun and 
stimulates  CRE-dependent  transcription.  Identification  of 
both  Cre-BP1  and  c-Jun  TREs  in  genes  dysregulated  in 
Tob1-null mice is particularly interesting because c-Jun, a mem-
ber of the AP-1 complex, is necessary for liver regeneration 
by repressing p53/p21 and p38 MAPK (Stepniak et al., 2006). 
DISCUSSION
We hypothesized that repression of inhibitory signals was a 
key mechanistic paradigm during liver regeneration. To test 
this postulate, a screen was undertaken for genes that might   
be constitutive inhibitors of liver regeneration, i.e., repressed   
after liver injury. The antiproliferative molecule Tob1, a mem-
ber of the PC3/BTG1 family of antiproliferative molecules, 
was identified as potentially fulfilling these requirements.
Our major findings are that Tob1 acts as a constitutive 
repressor of hepatocyte proliferation after hepatectomy. Tob1 
protein levels decrease after hepatectomy, most likely as a re-
sult of protein degradation. Decreased Tob1 is necessary for 
normal liver regeneration, as the rate of hepatocyte prolifera-
tion is determined by endogenous Tob1 levels. Tob1 suppresses 
Cdk1 kinase activity and associates with Caf1 in the Cdk com-
plex. Further antiproliferative activities of Tob1 are likely a 
result of effects on a variety of cell cycle proteins, including the 
suppression of cyclin D1 and A2 and inhibition of E2F targets 
concerned with DNA synthesis.
These results are important for several reasons. Demon-
strating that levels of an inhibitory protein control the rate of 
hepatocyte proliferation after hepatectomy support a novel para-
digm in liver regeneration in which inhibitory factors must be 
actively suppressed for normal regeneration. This model is diffi-
cult to prove explicitly without reconstituting the gene in 
the null mouse. Our AAV-8 construct provides this functional-
ity and allows us to show that the proliferation rate depends 
directly on Tob1 levels. These results are in contrast to work 
with, for example, Socs3 and p21 (Stepniak et al., 2006; Riehle 
et al., 2008). In these cases, although null mice for either dem-
onstrate enhanced liver regeneration, protein levels actually in-
crease after hepatectomy, suggesting that their effect is indirect.
Two major findings point to a mechanism of action for 
Tob1. The first is that Tob1 binds to Caf1 within a complex 
with Cdk1. Cdk1 is a critical Cdk activated by cyclin A and 
then cyclin B to facilitate mitosis (Malumbres and Barbacid, 
2009). To determine the nature of this interaction, we exam-
ined kinase activity in the Tob1-null mice. Increased kinase 
activity in Tob1-null mice suggests that Tob1 acts to inhibit 
kinase activity, delaying cell cycle progression.
A defining aspect of Tob1 is that it seems to be a multifunc-
tional protein involved in a variety of cellular processes. In addi-
tion to its effect on kinase activity, we note that loss of Tob1 
influences the transcription of multiple genes important for cell 
cycle progression. Loss of Tob1 accelerates the rise in cyclin D1 
and A2 protein levels. In a similar fashion, loss of Tob1 acceler-
ates the rise in E2F targets, preferentially affecting those impor-
tant for DNA synthesis. Collectively, these results suggest that 
Tob1 represses the transcription of genes important for cell cycle 
progression. How Tob1 acts to do this is unclear. It is possible 
that a wide-ranging effect of Tob1 on RNA degradation might 
be responsible for effects on these multiple target genes. Alterna-
tively, Tob1 might directly affect a few transcription factors, for 
example, E2F, with multiple downstream effects.
Other antiproliferative proteins that may regulate cell cycle 
are influenced by loss of Tob1. These include p21, which sup-JEM VOL. 207, June 7, 2010 
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Kozak sequence. The PCR product was cloned into pAMP, an AAV2 vector 
plasmid in which expression is controlled by the highly specific MUP pro-
moter element (Ho et al., 2008). An AAV2-MUP-eGFP vector plasmid was 
constructed as a negative control. Both vectors were cross-packaged in AAV8 
via triple plasmid transfection into AAV-293 cells (Agilent Technologies). No 
helper virus was used. In brief, each AAV vector plasmid, an AAV2/8 rep/
cap plasmid providing AAV2 replicase and AAV8 capsid functions, and a 
third  plasmid  encoding  adenovirus  helper  functions,  pHelper  (Agilent 
Technologies), were cotransfected into 293 cells at a molar ratio of 1:1:1. 
Cells were harvested 48 h after transfection. Cell pellets were resuspended 
in  DME,  and  intracellular  virus  particles  released  by  three  consecutive 
rounds of freeze-thaw, followed by centrifugation at 13,000 rpm for 10 min 
to remove particulates. Vector stocks were stored at 80°C and titered   
by real-time PCR using an ABI Prism 7700 Sequence Detection system 
(Applied Biosystems).
Virus injections. MUP-Tob1-AAV8, MUP-eGFP-AAV8 (negative con-
trol), or vehicle (saline) was administered via tail veins as previously described 
(Ho et al., 2008). Injections were performed at 200 µl for a total dose of either 
5 × 1010 DRP or 2.5 × 1010 DRP. These amounts were chosen based on a 
linear relationship between MUP-eGFP-AAV8 injection amounts and fluo-
rescence at this dose. 2/3 hepatectomies were performed at the indicated 
times after virus injections. Excised livers were rinsed in PBS and snap frozen 
in liquid nitrogen or fixed in 10% neutral buffered formalin.
Immunohistochemistry. Staining for BrdU (BD) was performed on fixed 
paraffin-embedded liver sections according to the manufacturer’s instructions 
(rat ABC Staining System; Santa Cruz Biotechnology, Inc.). Primary anti-
body was rat anti–mouse BrDU (Santa Cruz Biotechnology, Inc.). Prolifera-
tion index was quantified as the percentage of labeled hepatocyte nuclei that 
stained with BrdU over at least three high-power fields (400×).
mRNA  isolation  and  real-time  RT-PCR  Total  mRNA  was  purified   
from 30 mg of liver tissue preserved in RNALater with the RNeasy Mini kit 
(QIAGEN). 1 µg mRNA was reverse transcribed to cDNA using a High   
Capacity cDNA Reverse Transcription kit (Applied Biosystems). An ABI 7700 
Sequence Detector (Applied Biosystems) was used for all real-time PCR. cDNA 
template was diluted 1:5 and amplified using inventoried Taqman gene expres-
sion assays (Applied Biosystems) under standard conditions. Gene expression 
levels were normalized to GAPDH using the comparative CT method. Data 
were analyzed using ABI Sequence Detector Software (Applied Biosystems).
Protein sample preparation, immunoprecipitation, and Western 
blot analysis. Whole cell liver lysates were prepared by homogenizing 50 mg 
of frozen liver tissue in lysis buffer (50 mM Tris, 100 mM NaCl, 5 mM 
EDTA, 10% glycerol, and 0.5% NP-40) containing phosphatase inhibitor 
(Thermo Fisher Scientific) and protease inhibitor cocktail (Roche). Samples 
were sonicated for 30 s and clarified by centrifugation. Protein concentration 
was determined with the DC assay kit (Bio-Rad Laboratories).
Nuclear and cytoplasmic fractions were prepared as previously described 
(Andrews and Faller, 1991), with some modification: liver tissue was homoge-
nized in hypotonic buffer (10 mM Tris, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT, and 0.1% NP-40) containing protease inhibitor cocktail and cells were 
allowed to swell on ice for 10 min. Nuclei were pelleted and the supernatant 
containing the cytoplasmic fraction cleared. Nuclei were resuspended and 
lysed with 1% NP-40 and the supernatant collected. Protein concentration 
was determined with a BCA kit (Thermo Fisher Scientific). Enrichment 
quality was determined by immunoblotting for -actin and histone H3. Pro-
tein was denatured and separated by SDS-PAGE in 10% Criterion XT Bis-Tris 
precast gels (Bio-Rad Laboratories) and transferred to nitrocellulose (Milli-
pore). All antibody dilutions were made in 5% milk in TBS buffer. Primary 
antibodies used were the following: mouse monoclonal anti-Tob1 (Abcam), 
rabbit anti-Smad1/5/8 (Santa Cruz Biotechnology, Inc.), mouse monoclo-
nal anti-cyclin D1 (Santa Cruz Biotechnology, Inc.), rabbit anti-cyclin A2 
(EMD), mouse monoclonal anti-actin (Sigma-Aldrich), goat anti-GAPDH 
The specific interaction between Tob1 and c-Jun remains 
unknown but potentially important.
Importantly, our data show that although Tob1 levels 
control the rate of hepatocyte proliferation, Tob1 does not 
ultimately control liver size. At baseline, livers in Tob1-null 
mice are normal size, and by 9 d after hepatectomy, livers in 
Tob1-null mice again return to normal size. In our hands, 
hepatocyte proliferation after hepatectomy begins >24 h after 
surgery and peaks at 48 h. Although there are studies indicat-
ing that peak proliferation occurs earlier, our results are con-
sistent with those of others (Lesurtel et al., 2006).
When analyzing our array data, we used a cutoff for dif-
ferential expression of an LCB of |1.2|. This was chosen as a 
stringent estimate and the actual difference in expression is 
likely much higher than this (Ramalho-Santos et al., 2002; 
Wang et al., 2006). In fact, choice of this cutoff was validated 
by extensive real-time data showing 85% concordance with 
the array data. Given the intrinsic limitations of these methods 
to corroborate each other as a result of alternative splicing, 
normalization choices, and the difficulty arrays have in detect-
ing low abundance transcripts, this concordance is consistent 
with other studies (Wang et al., 2006).
In summary, these results suggest a model in which Tob1 
antagonizes proliferative signals and directly suppresses cell 
cycle progression by binding to and modulating Cdk activity 
and inhibiting transcription of multiple proteins critical for cell 
cycle progression. These findings demonstrate that an inhibi-
tor of proliferation must be blocked or suppressed for normal 
liver regeneration. Restoration of liver mass after hepatectomy 
is therefore best thought of as a balance between stimulatory 
and inhibitory factors. In human diseases in which liver func-
tion and regeneration are suppressed, it may be that under-
standing this pathway could point to therapeutic modalities.
MATERIALS AND METHODS
Mice. Tob1-null mice on a C57BL/6 background were a gift from I. Bagchi 
(University of Illinois at Urbana-Champaign, Champaign, IL). These mice are 
derived from a line produced and maintained by T. Yamamoto (University of 
Tokyo, Tokyo, Japan; Yoshida et al., 2000). As described previously, Tob1-
deficient mice are predisposed to spontaneous tumor development in the liver 
and elsewhere (Yoshida et al., 2003a). Viral constructs work best in male mice; 
thus, all mice used in this study were male between 7 and 10 wk of age. Geno-
typing was performed as previously described (Yoshida et al., 2003a).
2/3 hepatectomy. All surgeries were performed according to the National 
Institutes of Health guidelines for the humane treatment of laboratory ani-
mals and with approval of the Harvard Institutional Animal Care and Use 
Committee. Mice were anesthetized with 60 mg/kg ketamine (Hospira) and 
7 mg/kg xylazine (Phoenix Pharmaceuticals) and positioned supine. A trans-
verse incision was made inferior to the xiphoid process, which was excised. 
The median and left lateral lobes of the liver were eviscerated and ligated. At 
tissue recovery, mice were anesthetized and weighed. Livers were excised, 
rinsed, blotted, and weighed. Sections were snap frozen in liquid nitrogen, 
fixed in 10% neutral buffered formalin, or preserved in RNALater (QIAGEN). 
Mortality was <5% and not associated with a particular genotype.
AAV8 vector production: subcloning and packaging. A 2,300-bp mu-
rine Tob1 cDNA was obtained from the American Type Culture Collection. 
The 1,090-bp coding sequence was reframed via PCR to eliminate the un-
translated regions and provide new flanking restriction sites and an optimized 1206 Tob1 regulates liver regeneration | Ho et al.
Data analysis. All comparisons were performed using a two-tailed unpaired 
Student’s t test. All statistical tests used at least three and as many as nine dif-
ferent samples for each time point and genotype. * in the figures denotes sta-
tistical significance as defined by P < 0.05. All error bars in the figures are 
standard error.
Online supplemental material. Figs. S1 and S2 show mRNA or protein 
expression patterns after hepatectomy in Tob1-null mice for three proteins 
known to be important for liver regeneration: IL-6, Socs 3, and p27. Fig. S3 
shows real-time PCR validation of 20 genes found to be regulated using 
gene array analysis after hepatectomy in Tob1-null mice compared with   
WT mice. Fig. S4 examines categories of E2F targets differentially induced 
after hepatectomy in Tob1-null mice compared with WT mice. Table S1 
shows transcription factors expected to bind to putative promoter regions 
in the genes differentially induced 24 h after hepatectomy in Tob1-null   
mice compared with WT mice. Table S2 shows pathways regulated differ-
ently after hepatectomy in Tob1-null mice compared with wild-type mice.   
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20092434/DC1.
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